Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q3 2025 earnings

Reported October 9, 2025 · Before market open

Revenue$7.9MMiss by $4.4M
EPS-$1.03Miss by $0.19
Revenue estimate$12.3M
EPS estimate-$0.84

Next report

Oct 8, 2026 (In 2 weeks)
Revenue estimate$24.3M
EPS estimate-$0.60

Financials

Q3 2025

Income statement

See full
Revenue$7.9M-37.3%
Operating income-$91.4M-67.3%
Net income-$86.4M-76.5%
EPS (diluted)-$1.03-53.7%

Balance sheet

See full
Cash & equivalents$79.4M-20.6%
Total debt$56.5M+108%
Total equity$372.3M-1.2%
Total assets$522.5M+1.7%

Cash flow

See full
Operating cash flow-$57.4M-36.1%
CapEx$2.7M+15.5%
Free cash flow-$60.1M-35.0%

Valuation & ratios

Valuation

as of 08/31/25
See full
Market cap$714.04M-61.1%
Enterprise value$691.12M-60.8%
P/S8.5×-24.0×

Profitability

See full
Operating margin-319.3%-20.9pp
Net margin-292.5%-18.5pp
FCF margin-288.4%—

Returns & leverage

See full
Return on equity-65.4%+9.6pp
Debt / equity0.2×+0.1×
Current ratio5.4×+0.1×

FAQ

When did Nurix Therapeutics, Inc. report Q3 2025 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q3 2025 earnings on October 9, 2025 before market open.
What were Nurix Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $7.9M and eps of $-1.03 for Q3 2025.
Did Nurix Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $12.3M by $4.4M. EPS missed the consensus estimate of $-0.84 by $0.19.
How did Nurix Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 37.3% from $12.6M a year earlier and eps declined 53.7% from $-0.67.
Where can I find Nurix Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001549595-25-000112) and the 10-Q periodic report (0001549595-25-000113) directly on SEC EDGAR. The filing index links above go to sec.gov.